In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2.

Autor:	Mohd Abd Razak, Mohd Ridzuan, Md Jelas, Nur Hana, Norahmad, Nor Azrina, Mohmad Misnan, Norazlan, Muhammad, Amirrudin, Padlan, Noorsofiana, Sa'at, Muhammad Nor Farhan, Zainol, Murizal, Syed Mohamed, Ami Fazlin
Předmět:	INFLAMMATION prevention IN vitro studies LIQUID chromatography-mass spectrometry NITRIC oxide DATA analysis RESEARCH funding REVERSE transcriptase polymerase chain reaction TOLL-like receptors DESCRIPTIVE statistics PHYTOCHEMICALS PLANT extracts CELL lines CELL culture MEDICINAL plants DRUG efficacy PROTEOLYTIC enzymes ONE-way analysis of variance STATISTICS PHENOLS GENETIC mutation CELL survival COVID-19 SARS-CoV-2 REGRESSION analysis
Zdroj:	BMC Complementary Medicine & Therapies; 9/11/2024, Vol. 24 Issue 1, p1-13, 13p
Abstrakt:	Background: In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Methods: Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. Results: The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. Conclusions: In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu